Latest RA CAPITAL MANAGEMENT, L.P. Stock Portfolio

$7.56Billion– No. of Holdings #78

RA CAPITAL MANAGEMENT, L.P. Performance:

2024 Q2: -5.66%YTD: 6.72%2023: -2.79%

Performance for 2024 Q2 is -5.66%, and YTD is 6.72%, and 2023 is -2.79%.

About RA CAPITAL MANAGEMENT, L.P. and 13F Hedge Fund Stock Holdings

RA CAPITAL MANAGEMENT, L.P. is a hedge fund based in BOSTON, MA. On 03-Apr-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $9.7 Billions. In it's latest 13F Holdings report, RA CAPITAL MANAGEMENT, L.P. reported an equity portfolio of $7.6 Billions as of 30 Jun, 2024.

The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , PCVX, JANX. The fund has invested 18.2% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 8.2% of portfolio in VAXCYTE INC.

The fund managers got completely rid off INHIBRX INC (INBX), MADRIGAL PHARMACEUTICALS INC (MDGL) and CYTEK BIOSCIENCES INC (CTKB) stocks. They significantly reduced their stock positions in CYBIN INC (CYBN), UNICYCIVE THERAPEUTICS INC (UNCY) and ITEOS THERAPEUTICS INC (ITOS). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in RECURSION PHARMACEUTICALS-A (RXRX), ARCELLX INC (ACLX) and TOURMALINE BIO INC. The fund showed a lot of confidence in some stocks as they added substantially to BICYCLE THERAPEUTICS PLC-ADR (BCYC), ELIEM THERAPEUTICS INC (ELYM) and ACRIVON THERAPEUTICS INC.

RA CAPITAL MANAGEMENT, L.P. Equity Portfolio Value

Last Reported on: 14 Aug, 2024

RA CAPITAL MANAGEMENT, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that RA CAPITAL MANAGEMENT, L.P. made a return of -5.66% in the last quarter. In trailing 12 months, it's portfolio return was 14.6%.

New Buys

Ticker	$ Bought
recursion pharmaceuticals-a	115,385,000
arcellx inc	88,525,500
tourmaline bio inc	32,650,600
nurix therapeutics inc	13,565,500
insmed inc	13,400,000
zura bio ltd	11,261,300
nuvalent inc-a	9,087,190
perceptive capital solutions	7,545,000

New stocks bought by RA CAPITAL MANAGEMENT, L.P.

Additions

Ticker	% Inc.
bicycle therapeutics plc-adr	181
eliem therapeutics inc	138
acrivon therapeutics inc	73.38
avidity biosciences inc	64.54
alto neuroscience inc	50.53
sera prognostics inc-a	49.83
praxis precision medicines i	49.16
evolent health inc - a	48.44

Additions to existing portfolio by RA CAPITAL MANAGEMENT, L.P.

Reductions

Ticker	% Reduced
cybin inc	-24.31
unicycive therapeutics inc	-24.16
iteos therapeutics inc	-20.37
metagenomi inc	-15.29
cervomed inc	-5.16
apogee therapeutics inc	-0.81

RA CAPITAL MANAGEMENT, L.P. reduced stake in above stock

Sold off

Ticker	$ Sold
vaxart inc	-20,000,000
cytek biosciences inc	-45,691,100
black diamond therapeutics i	-17,875,600
inhibrx inc	-91,939,100
curevac nv	-5,956,090
eyepoint pharmaceuticals inc	-19,400,700
igm biosciences inc	-9,046,880
compass pathways plc	-6,584,110

RA CAPITAL MANAGEMENT, L.P. got rid off the above stocks

Sector Distribution

RA CAPITAL MANAGEMENT, L.P. has about 66.8% of it's holdings in Healthcare sector.

Sector	%
Healthcare	66.8
Others	32
	1.2

Market Cap. Distribution

RA CAPITAL MANAGEMENT, L.P. has about 3.2% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
UNALLOCATED	34.1
MID-CAP	30.9
SMALL-CAP	26.4
MICRO-CAP	5.1
LARGE-CAP	3.2

Stocks belong to which Index?

About 55.7% of the stocks held by RA CAPITAL MANAGEMENT, L.P. either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	52.7
Others	44.3
S&P 500	3

Top 5 Winners (%)		%
INSM	insmed inc	151.9 %
RNA	avidity biosciences inc	57.7 %
THRD	third harmonic bio inc	37.7 %
NRIX	nurix therapeutics inc	37.5 %
ELYM	eliem therapeutics inc	29.7 %

Top 5 Winners ($)		$
RNA	avidity biosciences inc	80.7 M
PCVX	vaxcyte inc	59.1 M
ELYM	eliem therapeutics inc	51.2 M
GERN	geron corp	43.4 M
DYN	dyne therapeutics inc	43.2 M

Top 5 Losers (%)		%
AVTE	aerovate therapeutics inc	-94.2 %
MGNX	macrogenics inc	-71.1 %
HOWL	werewolf therapeutics inc	-62.4 %
VOR	vor biopharma inc	-57.8 %
SLDB	solid biosciences inc	-57.4 %

Top 5 Losers ($)		$
AVTE	aerovate therapeutics inc	-248.2 M
EVH	evolent health inc - a	-92.0 M
FDMT	4d molecular therapeutics in	-55.1 M
NKTX	nkarta inc	-52.9 M
ETNB	89bio inc	-47.1 M

RA CAPITAL MANAGEMENT, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL MANAGEMENT, L.P. has 78 stocks in it's portfolio. About 53.9% of the portfolio is in top 10 stocks. AVTE proved to be the most loss making stock for the portfolio. RNA was the most profitable stock for RA CAPITAL MANAGEMENT, L.P. last quarter.

Last Reported on: 14 Aug, 2024

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ABOS	acumen pharmaceuticals inc	0.48	14,932,100	36,135,600	unchanged	0.00

ACET	adicet bio inc	0.12	7,541,000	9,124,610	unchanged	0.00

ACLX	arcellx inc	1.17	1,604,010	88,525,500	new

ANTX	an2 therapeutics inc	0.16	5,551,300	11,935,300	unchanged	0.00

ARVN	arvinas inc	0.15	421,348	11,216,300	unchanged	0.00

ATXS	astria therapeutics inc	0.61	5,043,760	45,898,200	added	14.29

AVTE	aerovate therapeutics inc	0.20	9,192,090	15,258,900	added	11.23

AXSM	axsome therapeutics inc	1.06	1,000,000	80,500,000	unchanged	0.00

BCYC	bicycle therapeutics plc-adr	0.60	2,253,000	45,600,700	added	181

BDTX	black diamond therapeutics i	0.00	0.00	0.00	sold off	-100

BIIB	biogen inc	3.01	982,139	227,679,000	added	32.59

CCCC	c4 therapeutics inc	0.30	4,878,000	22,536,400	unchanged	0.00

CMPS	compass pathways plc	0.00	0.00	0.00	sold off	-100

CMRX	chimerix inc	0.10	8,800,000	7,708,800	unchanged	0.00

CTKB	cytek biosciences inc	0.00	0.00	0.00	sold off	-100

CVAC	curevac nv	0.00	0.00	0.00	sold off	-100

CYBN	cybin inc	0.16	44,004,500	11,925,200	reduced	-24.31

DAWN	day one biopharmaceuticals i	1.44	7,871,720	108,472,000	added	0.79

DYN	dyne therapeutics inc	2.82	6,049,200	213,476,000	added	22.09

ELYM	eliem therapeutics inc	2.96	31,419,300	223,391,000	added	138